Regeneron Pharmaceuticals (REGN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $14.29
- Estimate
- $10.21
- Surprise
- +40.0%
- Revenue (period 2026-06-30)
- $4.29B
- Score at report (before → after)
- 6.1 → 6.2/10
Revenue source: xbrl.
How the report landed
Regeneron Pharmaceuticals (REGN) beat the $10.21 estimate with adjusted EPS of $14.29 — a large 40.0% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.1/10) to Hold at 6.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates REGN Hold at 6.1/10.
4 of the last 4 quarters beat the estimate; this quarter's +40.0% surprise compares with a +18.9% four-quarter average. Next scheduled report: 2026-10-30.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.3 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Analyst target reached - limited upside remaining
- Weak growth
- Target reached (-1.7% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $790.74
- Stop
- $746.84
The stock trades at 19.7× trailing but 12.9× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-17 — shown for context, not personalized investment advice.
REGN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $81.99B
- P/E (fwd)
- 12.9
- P/E (ttm)
- 19.7
- 52-week range
- $566.11–$859.34
- Off 52-week high
- 8.0%
- RSI (14)
- 64
- Volume vs avg
- 0.92×
- Score today
- 6.1/10